Business News • PR NewsWire • Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

RARITAN, N.J., June 11, 2016 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen), today announced real-world and clinical findings showing that people with type 2 diabetes treated with INVOKANA® (canagliflozin) achieved greater blood glucose control and were more likely to...

View More : http://www.prnewswire.com/news-releases/janssen-presents-new-data-showing-invokana-canagliflozin-is-associated-with-grea...

Releted News by prnewswire

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

Home Use of a Dual Hormone, Bionic Pancreas Safely Reduces Blood Glucose Levels and Hypoglycemia in Adults While Continuing Normal Daily Activities

Ronald McDonald House Charities® Of Southern California Awards 94 Scholarships To Deserving High School Seniors